Ben Auspitz


Ben Auspitz is a Partner at F-Prime Capital, and has worked in pharmaceuticals and life-science for over fifteen years, both in industry, as a consultant, and as an investor. Most recently before joining F-Prime Capital, he served as Therapeutic Area Head for Immuno-Inflammatory products at CombinatoRx Inc. during its growth from an angel-backed start-up to a publicly-listed company. In this role, he oversaw the advancement of seven programs from assay stage into phase II clinical studies, and was co-inventor on 15 product patents. Ben focuses on therapeutics, with a particular interest in Series A and company formation — including first venture investments in Ultragenyx, REGENX Biosciences, Symbiomix Therapeutics, Precision Biosciences, Unum Therapeutics, and Dimension Therapeutics, where he was a company founder and chairman.

He currently serves on the Board of Directors of Unum Therapeutics, Precision Biosciences, and Symbiomix Pharmaceuticals. Previously, Ben was involved in F-Prime Capital investments in Bikam Pharmaceuticals (acquired by Shire), Ligocyte Pharmaceuticals (acquired by Takeda), Respivert (acquired by Johnson and Johnson), Blueprint Medicine (NASDAQ: BPMC), Coherus Biosciences (NASDAQ: CHRS), REGENXBio (NASDAQ: RGNX), Dimension Therapeutics (NASDAQ:DMTX), and Ultragenyx (NASDAQ: RARE)

He holds a B.A. from Harvard University.

Back